PILA PHARMA AB (DE:5KC)

FRANKFURT:5KC

5KC

PILA PHARMA AB

RESEARCH TOOLSreports

Want to see DE:5KC full AI Analyst Report?

PILA PHARMA AB (5KC) Price & Analysis

0 Followers

5KC Stock Chart & Stats

€0.20

€0.09(20.09%)

At close: Jan 08 4:00 PM EST

€0.20

€0.09(20.09%)

Day’s Range― - ―

52-Week Range€0.09 - €0.41

Previous CloseN/A

Volume2.28K

Average Volume (3M)0.00

Market Cap

€6.87M

Enterprise Value€50.34M

Total Cash (Recent Filing)€1.08M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta0.57

Next Earnings

Aug 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares Outstanding45,682,120

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio-0.37

Price to Book (P/B)4.82

Price to Sales (P/S)63.25

P/FCF Ratio-7.76

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage / Zero DebtA zero-debt capital structure materially lowers bankruptcy and interest-rate risk for a cash-burning biotech. This durable strength preserves strategic optionality to fund clinical programs, negotiate partnerships, or raise equity without immediate debt-servicing pressure.

Material Equity Increase Supporting SolvencyA step-up in shareholders' equity strengthens the balance sheet and extends runway versus prior periods. Higher equity reduces short-term solvency risk, giving management more time to progress XEN-D0501 clinical milestones before needing dilutive financing.

Revenue Rebound In 2025A return to revenue growth signals improving operational traction or milestone activity, which can validate development progress. While still small, a sustained upward trend would reduce binary outcome dependence and support partnering or licensing discussions.

Bears Say

Widening Net LossesDeepening annual losses reflect heavy R&D and operating spend that will erode equity if unchecked. Persistently widening deficits increase the likelihood of dilutive capital raises and heighten execution risk for late-stage development plans.

Persistent Negative Cash GenerationConsecutive years of negative operating and free cash flow indicate structural cash burn tied to development activities. This pattern creates ongoing reliance on external capital and can constrain long-term program pacing if funding windows narrow.

No Material Recurring Commercial RevenueThe company is R&D-stage with no approved products or steady commercial cashflows. That structural revenue absence concentrates value on binary clinical outcomes and partnerships, increasing financing frequency and execution risk over the medium term.

5KC FAQ

What was PILA PHARMA AB’s price range in the past 12 months?

PILA PHARMA AB lowest stock price was €0.09 and its highest was €0.41 in the past 12 months.

What is PILA PHARMA AB’s market cap?

PILA PHARMA AB’s market cap is €6.87M.

When is PILA PHARMA AB’s upcoming earnings report date?

PILA PHARMA AB’s upcoming earnings report date is Aug 20, 2026 which is in 111 days.

How were PILA PHARMA AB’s earnings last quarter?

PILA PHARMA AB released its earnings results on Feb 26, 2026. The company reported -€0.034 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.034.

Is PILA PHARMA AB overvalued?

According to Wall Street analysts PILA PHARMA AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does PILA PHARMA AB pay dividends?

PILA PHARMA AB does not currently pay dividends.

What is PILA PHARMA AB’s EPS estimate?

PILA PHARMA AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does PILA PHARMA AB have?

PILA PHARMA AB has 45,682,120 shares outstanding.

What happened to PILA PHARMA AB’s price movement after its last earnings report?

PILA PHARMA AB reported an EPS of -€0.034 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.869%.

Which hedge fund is a major shareholder of PILA PHARMA AB?

Currently, no hedge funds are holding shares in DE:5KC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

PILA PHARMA AB

PILA PHARMA AB (publ) operates as a clinical stage pharmaceutical company in Sweden. It is developing XEN-D0501, a TRPV1 antagonist that has completed two phase 2a clinical trials for type 2 diabetes. PILA PHARMA AB (publ) was incorporated in 2014 and is based in Malmö, Sweden.